Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - PLURISTEM THERAPEUTICS INC | exhibit_32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - PLURISTEM THERAPEUTICS INC | exhibit_32-1.htm |
| EX-31.3 - EXHIBIT 31.3 - PLURISTEM THERAPEUTICS INC | exhibit_31-3.htm |
| EX-31.2 - EXHIBIT 31.2 - PLURISTEM THERAPEUTICS INC | exhibit_31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - PLURISTEM THERAPEUTICS INC | exhibit_31-1.htm |
| EX-23.1 - EXHIBIT 23.1 - PLURISTEM THERAPEUTICS INC | exhibit_23-1.htm |
| EX-10.41 - EXHIBIT 10.41 - PLURISTEM THERAPEUTICS INC | exhibit_10-41.htm |
| EX-10.40 - EXHIBIT 10.40 - PLURISTEM THERAPEUTICS INC | exhibit_10-40.htm |
| 10-K - 10-K - PLURISTEM THERAPEUTICS INC | zk1720512.htm |
Exhibit 32.3
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
18 U.S.C. SECTION 1350
In connection with the Annual Report on Form 10-K of Pluristem Therapeutics Inc. (the "Company") for the period ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350 that, to my knowledge:
|
1.
|
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
2.
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: September 7, 2017
|
|
By: /s/ Erez Egozi
Erez Egozi
Chief Financial Officer
|